

# Fady I Malik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5075456/publications.pdf>

Version: 2024-02-01

17  
papers

1,750  
citations

687363

13  
h-index

888059

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1776  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 2212-2220.	2.2	10
2	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 5006-5016.	2.2	15
3	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 287-299.	1.7	42
4	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	27.0	381
5	Pathogenic variants in <i>TNNC2</i> cause congenital myopathy due to an impaired force response to calcium. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
6	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.	2.8	73
7	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <i>GALACTIC-HF</i> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	7.1	47
8	Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 329-340.	4.1	100
9	Functional Characterization of the Intact Diaphragm in a Nebulin-Based Nematode Myopathy (NM) Model-Effects of the Fast Skeletal Muscle Troponin Activator tirasemtiv. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5008.	4.1	4
10	A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 584-594.	1.7	29
11	<i>CK2127107</i> amplifies skeletal muscle response to nerve activation in humans. <i>Muscle and Nerve</i> , 2018, 57, 729-734.	2.2	56
12	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , 2016, 388, 2895-2903.	13.7	229
13	Fast Skeletal Muscle Troponin Activator tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model. <i>PLoS ONE</i> , 2014, 9, e96921.	2.5	50
14	Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations. <i>Journal of Medical Genetics</i> , 2013, 50, 383-392.	3.2	46
15	Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy. <i>Brain</i> , 2013, 136, 1718-1731.	7.6	55
16	Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. <i>Nature Medicine</i> , 2012, 18, 452-455.	30.7	113
17	Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure. <i>Science</i> , 2011, 331, 1439-1443.	12.6	489